Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M97,404Revenue (TTM) $M25,638Net Margin (%)23.2Altman Z-Score2.0
Enterprise Value $M127,823EPS (TTM) $3.6Operating Margin %36.6Piotroski F-Score6
P/E(ttm)17.0Beneish M-Score-2.4Pre-tax Margin (%)30.8Higher ROA y-yN
Price/Book21.710-y EBITDA Growth Rate %--Quick Ratio1.5Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %9.5Current Ratio1.7Lower Leverage y-yY
Price/Free Cash Flow15.4y-y EBITDA Growth Rate %23.9ROA % (ttm)9.7Higher Current Ratio y-yY
Dividend Yield %3.8PEG1.8ROE % (ttm)117Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M1,594ROIC % (ttm)21.9Gross Margin Increase y-yN

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ABBV is held by these investors:



ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CHASE WILLIAM JEVP, CFO 2016-12-02Sell6,600$59.194.46view
HURWICH THOMAS A.VP, Controller 2016-11-16Sell3,100$62-0.27view
Schumacher Laura JExecutive Vice President 2016-09-07Sell50,000$65-4.88view
Schumacher Laura JExecutive Vice President 2016-06-24Sell186,106$60.033view
GONZALEZ RICHARD AChairman of the Board and CEO 2016-06-02Sell285,953$63.82-3.12view
GONZALEZ RICHARD AChairman of the Board and CEO 2016-05-11Sell39,000$63.8-3.09view
HURWICH THOMAS A.VP, Controller 2016-05-10Sell6,000$63.59-2.77view
RICHMOND TIMOTHY J.SVP, Human Resources 2016-05-10Sell21,583$63.52-2.66view
ALBAN CARLOSEVP, Commercial Operations 2016-05-10Sell47,438$63.52-2.66view
Schumacher Laura JExecutive Vice President 2016-03-08Sell25,000$56.0910.23view

Press Releases about ABBV :

Quarterly/Annual Reports about ABBV:

News about ABBV:

Articles On GuruFocus.com
AbbVie Declares Quarterly Dividend Feb 21 2017 
Galapagos NV Tests Cystic Fibrosis Treatment on First Patient Feb 03 2017 
AbbVie's Hepatitis C Treatment Under FDA Review Feb 02 2017 
Is Abbott Labs or AbbVie the Better Investment? Jan 31 2017 
AbbVie to Start Study on Alzheimer's Treatment Jan 29 2017 
AbbVie Reports 4th-Quarter 2016 Results Jan 27 2017 
AbbVie's Hepatitic C Treatment Under Accelerated Review by EMA Jan 24 2017 
Abbott Laboratories: An Undervalued Diamond in Overvalued Markets Jan 24 2017 
AbbVie Increases Price of Humira Jan 23 2017 
AbbVie Gets FDA Approval for Lymphoma Drug Jan 22 2017 

More From Other Websites
AbbVie Declares Quarterly Dividend Feb 21 2017
AbbVie Inc (ABBV) In Share Buyback Plan For The Third Year In A Row Feb 21 2017
AbbVie, Inc. breached its 50 day moving average in a Bullish Manner : ABBV-US : February 21, 2017 Feb 21 2017
8:00 am AbbVie authorizes a $5 bln increase to AbbVie's existing stock repurchase program Feb 20 2017
ABBVIE INC. Files SEC form 10-K, Annual Report Feb 17 2017
Parsabiv Is Expected to Boost Amgen’s Revenues in 2017 Feb 17 2017
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira Feb 17 2017
AbbVie Announces $5 Billion Increase to Stock Repurchase Program Feb 17 2017
NICE Rejects AbbVie’s Leukemia Drug Venclexta Feb 16 2017
UK National Institute For Health And Care Excellence Rejects Leukemia Drug From AbbVie Inc (ABBV) Feb 16 2017
AbbVie Declares Quarterly Dividend Feb 16 2017
Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone Feb 16 2017
Eli Lilly Is Great Stock to Buy Now Feb 15 2017
AbbVie to Present at the Cowen and Company 37th Annual Health Care Conference Feb 15 2017
These drug and medical device companies made the most payments to N.Y.C. hospitals Feb 14 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)